"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
(Generic versions may still be available.)
Fluothane Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Fluothane (halothane) is an inhalation anesthetic used to induce and maintain general anesthesia. The brand name of this medication is discontinued, but generic versions may be available. Common side effects include cardiac arrhythmias, slow heart rate, low blood pressure, shivering, nausea, and vomiting.
The induction dose of Fluothane varies from patient to patient but is usually within the range of 0.5% to 3%. The maintenance dose varies from 0.5% to 1.5%. Fluothane may interact with aminoglycosides, tubocurarine, adrenaline, other sympathomimetics, aminophylline, theophylline, and tricyclic antidepressants. Tell your doctor all medications and supplements you use. During pregnancy, Fluothane should be administered only if prescribed, it is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.
Our Fluothane (halothane) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Fluothane FDA Prescribing Information: Side Effects
As with other agents of this type, halothane anaesthesia has been shown to trigger a skeletal muscle hypermetabolic state leading to high oxygen demand and the clinical syndrome known as malignant hyperthermia (MH). The syndrome includes non specific features such as hypercapnia, muscle rigidity, tachycardia, tachypnoea, cyanosis, arrhythmias and unstable blood pressure. An increase in overall metabolism may be reflected in an elevated temperature. Treatment includes discontinuation of triggering agents, administration of intravenous dantrolene sodium and application of supportive therapy.
Cardiac arrhythmias, in particular ventricular arrthymias, have been reported as being very common during FLUOTHANE (halothane) use. Typically these are without clinical consequences. Bradycardia and/or hypotension may occur during FLUOTHANE (halothane) anaesthesia. Hypotension may occur particularly during induction.
Shivering may be observed during recovery from anaesthesia, especially if the patient is in cool surroundings.
Post-operative nausea and vomiting may occur after FLUOTHANE anaesthesia.
Anaesthesia with halothane may be followed by abnormalities of liver function or more rarely liver damage (see Contraindications).
Read the entire FDA prescribing information for Fluothane (Halothane) »
Additional Fluothane Information
Report Problems to the Food and Drug Administration
Find out what women really need.